BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 15.07B |
| Revenue (ttm) | 1.84B |
| Net Income (ttm) | 795.09M |
| Shares Out | 181.77M |
| EPS (ttm) | 4.20 |
| PE Ratio | 19.60 |
| Forward PE | 86.96 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $82.30 |
| Previous Close | $81.96 |
| Change ($) | 0.34 |
| Change (%) | 0.41% |
| Day's Open | 82.13 |
| Day's Range | 81.59 - 82.55 |
| Day's Volume | 113,470 |
| 52-Week Range | 71.35 - 131.94 |
SAN RAFAEL, Calif., June 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on Ju...
SAN RAFAEL, Calif., May 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.
The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.
We believe that BioMarin Pharmaceutical stock is a good buying opportunity at the present time. BMRN stock trades near $78 currently and it is, in fact, down 19% from its pre-Covid high of around $97 in...
The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec, gene therapy to treat severe hem...
SAN RAFAEL, Calif., May 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment o...
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for ad...
SAN RAFAEL, Calif., May 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results from an open-label Phase 1/2 study of valoctocog...
SAN RAFAEL, Calif., May 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.
SAN RAFAEL, Calif., May 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational g...
SAN RAFAEL, Calif., May 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.
BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.
BioMarin (BMRN) delivered earnings and revenue surprises of 75.00% and 9.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 79.55% over the past year to $0.09...
SAN RAFAEL, Calif., April 29, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $ 4...
SEATTLE and SAN RAFAEL, Calif., April 28, 2021 /PRNewswire/ -- The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Inst...
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN RAFAEL, Calif., April 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual ...
SAN RAFAEL, Calif., April 13, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a c...
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of ...
FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec investigational gene therapy for the treatment of...
SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-contro...
Biomarin Pharmaceutical (NASDAQ:BMRN) is currently down 7.49% to a price of $78.33. Friday the stock has been traded at a volume of 86.17 thousand, about 7.66% of its recent 30-day volume average of 1.1...
BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.
Biomarin Pharmaceutical (NASDAQ:BMRN) unveils its next round of earnings this Thursday, February 25. Get prepared with Benzinga's ultimate preview for Biomarin Pharmaceutical's Q4 earnings.
SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ...
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. BMRN: Which Stock Is the Better Value Option?
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Intel and BioMarin.
Shares of BioMarin Pharmaceuticals Inc. tumbled 6.6% in trading on Monday, the day after the company shared positive findings from a Phase 3 clinical trial evaluating the experimental drug Roctavian as ...
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophil...
SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene rox...
Firm also upped FibroGen stake in December
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, part...
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was annou...
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).
With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between ...
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise ... [Read more...]
| Industry Biotechnology | IPO Date Jul 23, 1999 |
| CEO Jean-Jacques Bienaime | Employees 3,059 |
| Stock Exchange NASDAQ | Ticker Symbol BMRN |
Analyst Forecasts
According to 23 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 107.00, which is an increase of 30.01% from the latest price.